Navigation Links
VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
Date:11/17/2009

MOUNTAIN VIEW, Calif., Nov. 17 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) plans to announce the results from the avanafil REVIVE (TA-301) phase 3 clinical trial on November 18th prior to market open. The announcement will be followed by a webcast and conference call at 8:30 a.m. Eastern time.

Conference Call Information

Domestic callers: 1-800-776-0853

International callers: 1-913-312-0980

Webcast information: http://ir.vivus.com. A webcast replay will be available on the VIVUS web site for 30 days.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.                Investor Relations:  The Trout Group
    Timothy E. Morris                               Brian Korb
    Chief Financial Officer                         646-378-2923
    650-934-5200

                                  Media Relations:  Pure Communications, Inc.
                                                    Dan Budwick
                                                    973-271-6085

SOURCE VIVUS, Inc.


'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. ViroPharma to Present at Three Upcoming Healthcare Conferences
11. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... IRVINE, Calif. , March 27, 2017  Cryoport, ... announced that it intends to offer shares of common ... shelf registration statement on file with the Securities and ... market and other conditions, and there can be no ... be completed, or as to the actual size or ...
(Date:3/27/2017)... MELVILLE, N.Y. , March 27, 2017 To ... U.S.A. , Inc., a leader in digital imaging ... Vision Expo East convention, held at New York,s ... 2, 2017. Save Your Vision Month, sponsored by the American ... health and the importance of receiving comprehensive eye exams. In ...
(Date:3/27/2017)... British Columbia, March 27, 2017  Sophiris Bio ... or "Sophiris"), a clinical late-stage biopharmaceutical company developing ... urological diseases, today reported fourth quarter and full ... Key Corporate Highlights: ... Localized Prostate Cancer. During 2016, the Company reported ...
Breaking Medicine Technology:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... organization of nurses and supply chain professionals, will hold their first Northeast Regional ... Analysis in Bundles.” , “Increasingly, supply chain and value analysis professionals have ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the ... including all stages, is more than 95%. Once the cancer spreads to other organs, ... 30%. To find out how to avoid this latter group, tune in to ...
(Date:3/27/2017)... Schwerzenbach, Switzerland (PRWEB) , ... March 27, 2017 ... ... the food industry. Conventional sodium testing methods are complicated and require expert user ... presents a new analytical method dedicated to the simplified, yet highly accurate, determination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... settlement agreement to resolve the pending litigation between itself and 1800 Vending DBA ... of Utah). , “I am thrilled to announce that we have now reached ...
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 to 2015, ... for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To combat the ... proposes a tax on prescription opioids to fund drug rehabilitation and prevention services.(3) ...
Breaking Medicine News(10 mins):